Related Experiment Video

Updated: Aug 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Androgen receptor as a therapeutic target for androgen independent prostate cancer

Nima Sharifi1, William L Farrar

  • 1Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. nima.sharifi@nih.gov

American Journal of Therapeutics
|April 29, 2006
PubMed

Insights

Advanced prostate cancer remains dependent on androgen receptor activity for growth, even at low testosterone levels. This review explores mechanisms of androgen receptor activation and potential therapeutic targets for novel prostate cancer treatments.

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Prostate cancer is a leading cause of cancer death in men.
  • Androgen deprivation therapy (ADT) is the primary treatment for advanced prostate cancer.
  • Cancers often develop resistance to ADT, progressing despite low testosterone levels.

Purpose of the Study:

  • To review evidence supporting continued androgen receptor (AR) dependence in castration-resistant prostate cancer (CRPC).
  • To explore mechanisms of AR activation in the absence of high androgen levels.
  • To identify potential therapeutic targets for novel treatments against advanced prostate cancer.

Main Methods:

  • Literature review of studies on prostate cancer progression and androgen receptor signaling.
  • Analysis of mechanisms driving AR activity in castration-resistant states.
  • Identification of therapeutic strategies targeting the AR pathway.

Main Results:

  • Evidence indicates that CRPC cells maintain AR activity for growth and survival.
  • Mechanisms include AR gene amplification, mutations, and alternative signaling pathways.
  • The AR pathway remains a viable target for therapeutic intervention in advanced prostate cancer.

Conclusions:

  • Androgen receptor signaling is crucial for the growth of advanced prostate cancer, even under castrate conditions.
  • Understanding AR activation mechanisms in CRPC is key to developing effective therapies.
  • Targeting the AR pathway offers promising avenues for novel prostate cancer treatments.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...